Glenn D. Rosen, MD

Associate Professor of Medicine
Stanford University School of Medicine
Stanford, California

Glenn D. Rosen, MD, is Associate Professor of Medicine, Interim Co-Chief, and Director of the Interstitial Lung Disease Program at Stanford University School of Medicine. The ILD center supports research and clinical care, and is actively involved in clinical trials in pulmonary fibrosis. He received his bachelor's degree and medical degree from the University of Pennsylvania in Philadelphia. He completed his residency in Internal Medicine at Graduate Hospital in Philadelphia, and performed his fellowships in Pulmonary Medicine at the University of California, San Francisco and Washington University in St. Louis, Missouri. Dr. Rosen is board certified in Internal Medicine with a subspecialty certification in Pulmonary Diseases.

Dr. Rosen has been awarded the Research Fellowship Grant Award and Career Investigator Award from the American Lung Association, the Stanford Institutional American Cancer Award, and the Jack Elway Memorial Fund Award for Lung Cancer Research. He is a member of various professional medical associations, including the American Thoracic Society and the American Society for Microbiology.

Dr. Rosen has been widely published in a number of peer-reviewed journals and publications on apoptosis, pulmonary fibrosis, and lung cancer. He serves on the editorial board of Cancer Biology and Therapy.

Disclosure Statement

The France Foundation relies upon faculty members to provide educational information in a manner that is objective and free from bias. In compliance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Commercial Support, all faculty members are required to disclose any conflicts of interest related to the context of their participation in a CME activity. Faculty members have disclosed the following relationships with commercial interests:

Glenn D. Rosen, MD, has served as a consultant for InterMune and has received honoraria from Boehringer Ingelheim, GlaxoSmithKline, Merck, Pfizer, and Schering-Plough.